01 — Analytics & Measurement

Pharma marketing analytics
built on data you can actually trust.

Many biopharma teams are operating on analytics that were configured once and never fully validated. Conversion rates don't make sense. Reporting doesn't align with business outcomes. PharmaForward builds the measurement foundation that makes every other decision reliable.

$1.10→$2.87
Proxy ROAS
90 days
40%
Cost per inquiry
Gene therapy
76%
CVR — fixed
to 11.4%
The problem

Your data is telling a story.
Just not the right one.

HIPAA limits what can be tracked. MLR review creates delays that mean tags are often wrong by the time they launch. Agencies implement GA4 to check a box, not to answer a question.

The result looks complete — sessions, conversions, cost-per-click — but doesn't connect to what the business is actually trying to achieve. How many patients found a treatment center? How many HCPs requested a rep? What is a treatment center search worth?

PharmaForward starts from the question your leadership actually needs answered — not from the data that's easiest to collect.

76.21%
Conversion rate in a live biopharma account when PharmaForward inherited it. The number was wrong — GA4-imported conversions double-counting micro-events. Three weeks later the real rate was 11.4%. The program had been optimized against a metric that didn't exist.

Your CVR looks high but nobody believes it. Double-counted micro-events, GA4-imported conversions, and misconfigured goals are the most common causes. We find them, document them, and fix them.

You have dashboards but no answers. Session counts and CTR tell you what happened. PharmaForward builds pharma marketing analytics that tells you why — and what to change.

You can't connect spend to outcomes. Without a proxy ROAS model, every budget conversation is a negotiation based on impressions. We assign dollar values to conversion events so every channel has an ROI number.

Your agencies report, but don't diagnose. Monthly summaries describe what happened. PharmaForward explains why — and recommends what to change before the next reporting cycle.

Cross-domain tracking is broken. Patients move between brand sites and support portals. Without cross-domain configuration, every session looks new and attribution breaks. We fix this at the GTM architecture level.

What’s included

Every layer of the
measurement stack.

Every layer of the measurement stack — built within HIPAA, GDPR, and MLR requirements from day one.

Foundation
GA4 Implementation & Audit
Google Tag Manager Architecture
Cross-Domain Tracking
Consent Management Setup
HIPAA-Aware Tagging
Data Layer Design
Container QA & Governance
Conversion Tracking
treatment center locator Event Tracking
HCP Rep Request Tracking
Patient Support Enrollment
Doctor Discussion Guide DL
Video Engagement Tracking
Form Completion Events
Micro-Conversion Deduplication
ROI Modeling
Proxy ROAS Framework
Conversion Value Assignment
Marketing Mix Modeling
Smart Bidding Migration
Channel Attribution Modeling
Budget Pacing Analysis
Executive ROI Narrative
Intelligence
Real-Time Dashboards
BigQuery Data Pipeline
Windsor.ai Integration
B2B HCP Visitor ID (Snitcher)
IQVIA Customer Match
Weekly KPI Pulse Reports
Competitive Intelligence
Case study
Rare disease · Gene therapy · 90-day sprint

Proxy ROAS from $1.10 to $2.87 — after fixing what nobody had noticed.

When PharmaForward inherited this account, it reported a 76.21% conversion rate. That number had been used to optimize Smart Bidding, allocate budget, and brief leadership for months. It was wrong.

GA4-imported conversions were double-counting micro-events. The HCP campaigns sat in the patient account. Parallel tracking had corrupted historical data. The program had been optimizing against a measurement layer that bore no relation to reality.

Phase one: full measurement rebuild — eight conversion actions recreated from scratch, native tags validated, and a proxy ROAS model built assigning dollar values to treatment center searches and patient support enrollments. Phase two: Smart Bidding migration once thirty days of clean data had accumulated. Within ninety days, proxy ROAS more than doubled.

Therapy areaSickle cell disease — gene therapy
Timeline90-day sprint
StackGA4 · GTM · Google Ads · Windsor.ai · BigQuery
ComplianceHIPAA-aware · MLR-reviewed · FDA fair balance
Proxy ROAS over time — engagement start marked
$2.87
Proxy ROAS
at 90 days
40%
Cost per inquiry
search
8
Conversion actions
rebuilt
How it works

Four phases. One reliable measurement layer.

01
Measurement Audit

Two to four weeks. Every tag, trigger, variable, and conversion action examined. Data quality scored. The gap between what your measurement reports and what's actually happening documented precisely.

02
Architecture Rebuild

Clean implementation from scratch or targeted remediation. Cross-domain tracking, consent management, HIPAA-aware configuration, conversion deduplication — built correctly, documented for your MLR team.

03
Proxy ROAS Modeling

Dollar values assigned to your specific conversion events — treatment center searches, HCP rep requests, patient support enrollments. Every channel gets an ROI number. Budget conversations get a foundation.

04
Ongoing Intelligence

Weekly KPI pulse reports, real-time dashboards, monthly strategic analysis. The measurement layer is not a project — it's a system that stays current as campaigns change, platforms update, and MLR requirements evolve.

FAQ

Questions about
pharma marketing analytics.

The questions biopharma analytics and marketing teams ask most often — answered directly.

Related: AI & Search Visibility  ·  Marketing Optimization

What is pharma marketing analytics? +
Pharma marketing analytics is the measurement architecture that connects biopharma digital marketing activity to business outcomes — tracking which programs drive qualified treatment center searches, HCP engagement, and patient conversion, and translating that into ROI metrics leadership can trust. Unlike consumer analytics, it must operate within HIPAA, GDPR, and FDA fair balance requirements from day one.
What is proxy ROAS and why does biopharma need it? +
Proxy ROAS is a measurement framework for biopharma programs that cannot track direct revenue. Dollar values are assigned to conversion events based on estimated business value — a treatment center locator search might be worth $150, a doctor discussion guide download $8. These assigned values create an ROI signal that connects digital spend to outcomes your CFO can understand, without HIPAA-restricted patient data.
What is marketing mix modeling in pharma? +
Marketing mix modeling in pharma uses statistical analysis to estimate how each channel contributes to overall brand performance. It is particularly valuable in biopharma because HIPAA limits deterministic attribution — MMM provides directional ROI signals across paid search, display, organic, and offline channels without patient-level tracking.
How do you measure pharma marketing ROI without patient data? +
PharmaForward uses proxy conversion events — assigning dollar values to actions like treatment center searches, HCP rep requests, and patient support enrollments. Combined with marketing mix modeling and channel spend data, this creates a measurable ROAS signal without HIPAA-restricted patient data. The methodology is proprietary PharmaForward IP, refined across active biopharma retainer engagements.
What analytics tools does PharmaForward use? +
PharmaForward builds on GA4 and Google Tag Manager, with BigQuery for data pipeline and Windsor.ai for multi-channel data integration. B2B HCP identification uses Snitcher via GTM. All implementations are HIPAA-aware, consent management is configured correctly, and IQVIA Customer Match is activated only with confirmed legal sign-off.
How long does a pharma analytics audit take? +
A full pharma marketing analytics audit typically takes two to four weeks — covering GA4, GTM, conversion actions, cross-domain tracking, and consent management across every property in scope. The output is a prioritized remediation roadmap with effort estimates. A 90-day implementation sprint then addresses the highest-priority work.

Start with a
measurement audit.

Two to four weeks across your biopharma properties. You’ll know exactly what’s broken and what it’s costing.

Connect with us